Ads
related to: herceptin, kadcyla- EMILIA Trial
See EMILIA Clinical Trial
Information on KADCYLA®.
- Proposed MOA
Learn About The Proposed Mechanism
Of Action For KADCYLA®.
- Dosing & Admin Guide
Download The Guide To Learn More
About The Dosing Schedule.
- Important Safety Info
See Full Prescribing Information
Including Boxed Warnings.
- Clinical Trial Info
Learn About the Latest EMILIA
Clinical Trial Info for KADCYLA®.
- Contact A Representative
Talk With A Representative
To Learn More About KADCYLA®.
- EMILIA Trial
Search results
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 8 hours agoResults for the ACE-Breast-02 study were presented at the American Society of Clinical Oncology 2024...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 1 day agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
Zacks via Yahoo Finance· 10 months agoSeagen Inc. SGEN announced positive top-line results from its late-stage HER2CLIMB-02 study,...
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Zacks via Yahoo Finance· 1 year agoRoche Holding AG’s RHHBY performance in 2022 was pretty average, as the demand for COVID-19 products...
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
Zacks via Yahoo Finance· 2 weeks agoRoche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced...
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
Zacks via Yahoo Finance· 2 years agoSwiss pharma giant Roche Holding AG’s RHHBY third-quarter revenues declined 6% to CHF 14.7 billion...
Seagen's breast cancer therapy succeeds in late-stage study
Reuters via Yahoo News· 10 months agoPfizer in March agreed to acquire Seagen and its targeted therapies in a $43 billion deal to help...
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
Zacks via Yahoo Finance· 6 months agoRoche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone...
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
Zacks via Yahoo Finance· 10 months agoRoche Holding AG’s RHHBY performance in the first half was average, as COVID-19 product related...
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Zacks via Yahoo Finance· 2 years agoShares of Puma Biotechnology PBYI were up 17.4% at market close on Aug 5, following the earnings...
Ads
related to: herceptin, kadcyla
